Fibromuscular dysplasia medical therapy: Difference between revisions
Jump to navigation
Jump to search
| (2 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Fibromuscular dysplasia}} | {{Fibromuscular dysplasia}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}{{M.B}} | ||
==Overview== | ==Overview== | ||
There is no treatment for FMD; the mainstay of therapy is management of manifestations of this condition. | There is no treatment for FMD; the mainstay of therapy is management of manifestations of this condition. For example: Pharmacologic medical therapies for treatment of [[renovascular hypertension]] in FMD patients include [[ACE inhibitor|ACE inhibitors]] and [[angiotensin receptor blockers]] (ARBs). | ||
For example: Pharmacologic medical therapies for treatment of [[renovascular hypertension]] in FMD patients include [[ACE inhibitor|ACE inhibitors]] and [[angiotensin receptor blockers]] (ARBs) | |||
==Medical Therapy== | ==Medical Therapy== | ||
*Pharmacologic medical therapies for treatment of [[renovascular hypertension]] in FMD patients include [[ACE inhibitor|ACE inhibitors]] and [[angiotensin receptor blockers]] (ARBs).If a second medication is needed, the addition of a [[thiazide diuretic]] is an acceptable choice. | *Pharmacologic medical therapies for treatment of [[renovascular hypertension]] in FMD patients include [[ACE inhibitor|ACE inhibitors]] and [[angiotensin receptor blockers]] (ARBs). If a second medication is needed, the addition of a [[thiazide diuretic]] is an acceptable choice.<ref>{{Cite journal | ||
| author = [[Jeffrey W. Olin]], [[Heather L. Gornik]], [[J. Michael Bacharach]], [[Jose Biller]], [[Lawrence J. Fine]], [[Bruce H. Gray]], [[William A. Gray]], [[Rishi Gupta]], [[Naomi M. Hamburg]], [[Barry T. Katzen]], [[Robert A. Lookstein]], [[Alan B. Lumsden]], [[Jane W. Newburger]], [[Tatjana Rundek]], [[C. John Sperati]] & [[James C. Stanley]] | |||
| title = Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association | |||
| journal = [[Circulation]] | |||
| volume = 129 | |||
| issue = 9 | |||
| pages = 1048–1078 | |||
| year = 2014 | |||
| month = March | |||
| doi = 10.1161/01.cir.0000442577.96802.8c | |||
| pmid = 24548843 | |||
}}</ref> | |||
*Among patients with an ischemic event, [[Antiplatelet drug|antiplatelet]] therapy is generally used. | *Among patients with an ischemic event, [[Antiplatelet drug|antiplatelet]] therapy is generally used. | ||
*For information on treatment of hypertension, '''''[[Chronic hypertension medical therapy|click here]]'''''. | |||
==References== | ==References== | ||
Latest revision as of 23:30, 19 August 2018
|
Fibromuscular dysplasia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
ASA/ACCF/AHA Guideline Recommendations |
|
Management of Patients With Fibromuscular Dysplasia of the Extracranial Carotid Arteries |
|
Case Studies |
|
Fibromuscular dysplasia medical therapy On the Web |
|
American Roentgen Ray Society Images of Fibromuscular dysplasia medical therapy |
|
Risk calculators and risk factors for Fibromuscular dysplasia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohsen Basiri M.D.
Overview
There is no treatment for FMD; the mainstay of therapy is management of manifestations of this condition. For example: Pharmacologic medical therapies for treatment of renovascular hypertension in FMD patients include ACE inhibitors and angiotensin receptor blockers (ARBs).
Medical Therapy
- Pharmacologic medical therapies for treatment of renovascular hypertension in FMD patients include ACE inhibitors and angiotensin receptor blockers (ARBs). If a second medication is needed, the addition of a thiazide diuretic is an acceptable choice.[1]
- Among patients with an ischemic event, antiplatelet therapy is generally used.
- For information on treatment of hypertension, click here.
References
- ↑ Jeffrey W. Olin, Heather L. Gornik, J. Michael Bacharach, Jose Biller, Lawrence J. Fine, Bruce H. Gray, William A. Gray, Rishi Gupta, Naomi M. Hamburg, Barry T. Katzen, Robert A. Lookstein, Alan B. Lumsden, Jane W. Newburger, Tatjana Rundek, C. John Sperati & James C. Stanley (2014). "Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association". Circulation. 129 (9): 1048–1078. doi:10.1161/01.cir.0000442577.96802.8c. PMID 24548843. Unknown parameter
|month=ignored (help)